CTLA4 and neoplasm: Second, the induction phase of ipilimumab plus nivolumab provides repeated CTLA‐4 blockade, in contrast to the single priming dose of tremelimumab in STRIDE, and may enhance de novo priming, expand tumor‐reactive clones, and reduce intratumoral regulatory T cells [3, 4, 13].